← ANALYST RATINGS · TIPRANKS
Phibro Animal Health (PAHC): analyst forecast and price target
Analyst consensus
Moderate Sell0 Buy0 Hold1 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $35.00, the highest $35.00, the lowest $35.00. The average is −9.8% from the last price of $38.82.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Ekaterina Knyazkova★★★★★★★★★★#10740 · hits 30% · avg −10.6% | J.P. Morgan | $55.00 | Buy | +41.7% | Reiterated | 16.10.26on TipRanks 07:55 | +3.3% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $35.00 | Sell | −9.8% | Reiterated | 27.08.26on TipRanks Aug 31 06:00 | +0.1%next day +3.9% · 5 days +6.2% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $39.00 → $40.00+2.6% | Buy | +3.0% | Reiterated | 27.08.26on TipRanks 06:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $37.00 → $38.00+2.7% | Hold | −2.1% | Reiterated | 27.08.26on TipRanks 06:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $38.00 → $39.00+2.6% | Hold | +0.5% | Reiterated | 27.08.26on TipRanks 06:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $36.00 → $39.00+8.3% | Hold | +0.5% | Reiterated | 27.08.26on TipRanks 06:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $39.00 → $41.00+5.1% | Buy | +5.6% | Reiterated | 27.08.26on TipRanks 06:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $39.00 → $40.00+2.6% | Buy | +3.0% | Reiterated | 27.08.26on TipRanks 06:05 | — | |
| Daniel Grosslight★★★★★★★★★★#4007 · hits 47% · avg +3.6% | Citi | $62.00 → $44.00−29.0% | Hold | +13.3% | Assigned | 14.05.26on TipRanks May 13 15:20 | −4.2%next day +1.7% · 5 days −4.0% | ↗ |
| Erin Wright★★★★★★★★★★#354 · hits 64% · avg +15.1% | Morgan Stanley | $45.00 → $49.00+8.9% | Hold | +26.2% | Reiterated | 06.02.26on TipRanks 09:45 | +4.2%next day −2.8% · 5 days −0.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Phibro Animal Health
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $45.00 at a price of $35.74 (+25.9%); now: $45.00 at $38.82 (+15.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 1 | 2 | 3 | 2 | 1 |
Earnings and sales forecast
Next report: 11.11.26 (Q1 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.78 (from $0.76 to $0.81). Last quarter: $0.85.
Sales
Next quarter’s sales estimate — $382M (from $382M to $383M). Last quarter: $397M.
Best top-analyst consensus in the sector · Healthcare
About Phibro Animal Health
- CEO: Daniel Bendheim
- Employees: 2,605
- Glenpointe Centre East, Teaneck, NJ, 07666-6712, US
- www.pahc.com
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an e
Data from the stock’s TipRanks forecast page, read 232 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗